Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
FOSTER CITY, Calif.–(BUSINESS WIRE)–
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern Time via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results, as well as business highlights and upcoming milestones, at 10:30 a.m. Eastern Time the same day.
A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.
Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL.
About Geron
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005103/en/
Aron Feingold
Investor and Media Relations
[email protected]
[email protected]
KEYWORDS: California United States North America
INDUSTRY KEYWORDS: Oncology Health Medical Devices Hospitals General Health Pharmaceutical Biotechnology
MEDIA:
| Logo |
 |